RTI Biologics Inc. (RTIX) reported fourth-quarter net income of $1.489 million or $0.03 per share compared to a net loss of $102.515 million or $1.89 per share last year.
On average, 8 analysts polled by Thomson Reuters expected the company to report profit of $0.04 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenues increased to $41.960 million from $37.363 million last year. Analysts expected revenue of $43.20 million for the quarter.
The company expects full year revenues for 2010 to increase between 5% and 7% on a constant currency basis. Assuming foreign currency exchange rates remain near year-end 2009 levels, the company estimates that foreign currency translation adjustments will increase revenues by approximately 1% for the full year 2010, resulting in reported revenue growth between 6% and 8%, or between $174.5 million and $177.5 million. Full year earnings per share are expected to be in the range of $0.15 to $0.17, based on 55.7 million fully diluted shares outstanding.
For comments and feedback: editorial@rttnews.com